Featured Studies Results
Cancer: Pancreatic
IGNITE-TX - Identifying Individuals for Genetic Testing for Familial Cancer
https://www.facingourrisk.org/research-clinical-trials/study/266 /helping-people-with-a-genetic-mutation-in-brca1-brca2-or-lynch-syndrome-talk-to-their-family-members-about-their-risk-for-cancer-and-find-the-best-way-to-get-family-members-tested
Clinicaltrials.gov identifier:
NCT07318363 (https://clinicaltrials.gov/show/NCT07318363)
Prevention
People with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome who have relatives who have not been tested
Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies
https://www.facingourrisk.org/research-clinical-trials/study/356 /treating-advanced-msi-high-or-dmmr-cancers-using-the-targeted-therapy-moma-341-given-alone-or-in-combination-with-standard-therapies
Clinicaltrials.gov identifier:
NCT06974110 (https://clinicaltrials.gov/show/NCT06974110)
Treatment
Treatment study for people with advanced or metastatic cancers
Multi-Cancer Detection Blood Tests in Adults Without Cancer: Vanguard Study
https://www.facingourrisk.org/research-clinical-trials/study/394 /multi-cancer-detection-blood-tests-in-adults-without-cancer-vanguard-study
Clinicaltrials.gov identifier:
NCT06995898 (https://clinicaltrials.gov/show/NCT06995898)
Prevention
A study testing two multi-cancer detection blood tests in people who do not have cancer
Please Help us Learn More About Immunotherapy Side Effects That People With Cancer Experience
https://www.facingourrisk.org/research-clinical-trials/study/421 /a-5-minute-patient-and-caregiver-survey-to-share-experiences-with-immunotherapy-and-any-short-term-or-long-term-side-effects
Surveys, Registries, Interviews
This 5-minute survey allows cancer patients on immunotherapy (currently or in the past) and their caregivers to share their experiences, including their side effects and whether they were resolved or not.
Testing the Drug CX-5461 for Treating Metastatic Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/431 /testing-the-drug-cx-5461-for-treating-metastatic-solid-tumors
Clinicaltrials.gov identifier:
NCT06606990 (https://clinicaltrials.gov/show/NCT06606990)
Treatment
Phase 1 study for treatment of advanced solid tumors
Using the Drug Daraxonrasib in Surgically Removed Pancreatic Cancer (RASolute 304)
https://www.facingourrisk.org/research-clinical-trials/study/389 /using-the-drug-daraxonrasib-in-surgically-removed-pancreatic-cancer-rasolute-304
Clinicaltrials.gov identifier:
NCT07252232 (https://clinicaltrials.gov/show/NCT07252232)
Treatment
Phase 3 study for pancreatic cancer treatment after surgery and chemotherapy
Comparing the Targeted Therapy Daraxonrasib With or Without Chemotherapy to Chemotherapy Alone for First-Line Treatment of Metastatic Pancreatic Cancer (RASolute 303)
https://www.facingourrisk.org/research-clinical-trials/study/407 /comparing-daraxonrasib-with-or-without-chemotherapy-to-chemotherapy-alone-for-first-line-treatment-of-metastatic-pancreatic-cancer
Clinicaltrials.gov identifier:
NCT07491445 (https://clinicaltrials.gov/show/NCT07491445)
Treatment
Phase 3 Study for First-Line Treatment of Metastatic Pancreatic Cancer
Testing a New Targeted Therapy ETX-19477 to Treat Advanced Breast, Colorectal Endometrial, Ovarian or Pancreatic Cancer in People with a BRCA2 Mutation (ERADIC8)
https://www.facingourrisk.org/research-clinical-trials/study/432 /testing-a-new-targeted-therapy-etx-19477-to-treat-advanced-solid-tumors-eradic8
Clinicaltrials.gov identifier:
NCT06395519 (https://clinicaltrials.gov/show/NCT06395519)
Treatment
Phase 1/2 treatment study for people with advanced breast, colorectal, endometrial, ovarian or pancreatic cancer
Study of a New Oral Medication, Daraxonrasib After Surgery to Help Prevent Pancreatic Cancer from Returning
https://www.facingourrisk.org/research-clinical-trials/study/378 /study-of-a-new-oral-medication-daraxonrasib-after-surgery-to-help-prevent-pancreatic-cancer-from-returning
Clinicaltrials.gov identifier:
NCT07252232 (https://clinicaltrials.gov/show/NCT07252232)
Treatment
Phase 3 treatment trial for pancreatic cancer that was removed by surgery
Comparing Two Vaccine Treatments With Immunotherapy for Pancreatic Cancer Before and After Surgery
https://www.facingourrisk.org/research-clinical-trials/study/386 /comparing-two-vaccine-treatments-with-immunotherapy-for-pancreatic-cancer-before-and-after-surgery
Clinicaltrials.gov identifier:
NCT06782932 (https://clinicaltrials.gov/show/NCT06782932)
Treatment
Phase 1b/2 treatment study for newly diagnosed pancreatic cancer that can be removed with surgery and who have not yet received treatment
Vaccine for People at High Risk for Pancreatic Cancer
https://www.facingourrisk.org/research-clinical-trials/study/365 /vaccine-for-those-at-high-risk-of-developing-pancreatic-cancer
Clinicaltrials.gov identifier:
NCT05013216 (https://clinicaltrials.gov/show/NCT05013216)
Prevention
Phase 1 pancreatic cancer prevention study for people at high risk
Using a Blood Test to Detect Early Cancer Recurrence After Treatment (ORACLE)
https://www.facingourrisk.org/research-clinical-trials/study/372 /using-a-blood-test-to-detect-early-cancer-recurrence-after-treatment-oracle
Clinicaltrials.gov identifier:
NCT05059444 (https://clinicaltrials.gov/show/NCT05059444)
Treatment
Post-treatment study to monitor for recurrence
An Early Detection and Prevention Study for People with an Increased Risk of Cancer (InAdvance)
https://www.facingourrisk.org/research-clinical-trials/study/385 /an-early-detection-and-prevention-study-for-people-with-an-increased-risk-of-cancer-inadvance
Clinicaltrials.gov identifier:
NCT05463796 (https://clinicaltrials.gov/show/NCT05463796)
Prevention
Study for people at risk of cancer, including previvors, survivors and family members
The EASE Study: Helping People with Advanced Cancer Cope with Fear of Cancer Progression
https://www.facingourrisk.org/research-clinical-trials/study/413 /the-ease-study-helping-people-with-advanced-cancer-cope-with-fear-of-cancer-progression
Clinicaltrials.gov identifier:
NCT07636200 (https://clinicaltrials.gov/show/NCT07636200)
Quality of Life
Quality of life study for people with advanced cancer experiencing anxiety
Treating Advanced Solid Tumors with a KRAS G12C Mutation Using Targeted Therapies Called RAS(ON) Inhibitors
https://www.facingourrisk.org/research-clinical-trials/study/409 /treating-advanced-solid-tumors-with-a-kras-g12c-mutation-using-targeted-therapies-called-rason-inhibitors
Clinicaltrials.gov identifier:
NCT06128551 (https://clinicaltrials.gov/show/NCT06128551)
Treatment
Phase 1/2 treatment study for advanced colorectal, pancreatic or lung cancer with a KRAS G12C mutation
Testing a KRAS Vaccine with Immunotherapy for Advanced Pancreatic and Colorectal Cancers with MMR‑Proficient (MMR‑p) Tumors
https://www.facingourrisk.org/research-clinical-trials/study/384 /testing-a-kras-vaccine-with-immunotherapy-for-advanced-pancreatic-and-colorectal-cancer
Clinicaltrials.gov identifier:
NCT06411691 (https://clinicaltrials.gov/show/NCT06411691)
Treatment
Phase 1b treatment study for previously-treated pancreatic or colorectal cancer with a KRAS mutation
Treating Advanced Breast Cancer or Other Solid Cancers Using a Combination of a New Targeted Therapy, ZEN003694, With The Targeted Therapy Abemaciclib (Verzenio)
https://www.facingourrisk.org/research-clinical-trials/study/363 /testing-a-new-drug-zen003694-with-chemotherapy-abemaciclib-for-people-with-advanced-or-inoperable-breast-cancer-and-other-solid-tumors
Clinicaltrials.gov identifier:
NCT05372640 (https://clinicaltrials.gov/show/NCT05372640)
Treatment
Phase 1 treatment study for advanced breast cancer and other solid tumors
Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/300 /study-of-a-new-investigationai-inhibitor-to-treat-people-with-advanced-solid-tumors
Clinicaltrials.gov identifier:
NCT05932862 (https://clinicaltrials.gov/show/NCT05932862)
Treatment
Treatment study for people with advanced solid tumors
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.